ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4

Journal of Coastal Life Medicine

Adverse Reactions from Anti-Tuberculosis Drugs in Patients with Pulmonary Tuberculosis

Received: 24 October 2022, **Revised:** 18 November 2022, **Accepted:** 28 December 2022

Tashpulatova Fatima Kudratovna
Doctor of Medical Sciences, Associate Professor of the Separtment of Infectious diseases, Children's infectious diseases, Phthisiatry and Pulmonology Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan
Email: tashpulatova@mail.ru

Keywords:

Adverse reactions, Anti-tuberculosis drugs, Pulmonary tuberculosis, Side effects, Treatment challenges, Patient management, Drug toxicity, Liver disease, Skin reactions, Drug interactions.

Abstract

This article focuses on the adverse reactions that patients with pulmonary tuberculosis may experience from anti-tuberculosis drugs. The study aims to identify the common adverse reactions, their severity, and the risk factors associated with their occurrence. By analyzing previous relevant studies and examining data on patients with pulmonary tuberculosis, the article highlights the importance of monitoring patients for adverse drug reactions and adjusting their treatment plan accordingly. The results indicate that the occurrence of adverse reactions is a common problem in patients with pulmonary tuberculosis, which can lead to treatment discontinuation and poor treatment outcomes. Therefore, healthcare providers need to be aware of these adverse reactions and implement proactive measures to minimize their impact on patients. Overall, this article provides valuable insights for clinicians who prescribe anti-tuberculosis drugs and aims to improve patient care and treatment outcomes.

1. Introduction

Pulmonary tuberculosis is a contagious infectious disease that affects the lungs. The disease is caused by the bacteria Mycobacterium tuberculosis and is spread through the air when an infected person coughs, sneezes, or talks. According to the World Health Organization (WHO), tuberculosis (TB) is one of the top ten causes of death worldwide, with approximately 1.4 million deaths reported in 2019 [1]. While effective treatment for TB exists, there are often significant side effects associated with anti-tuberculosis drugs.

Adverse reactions from anti-tuberculosis drugs have been widely reported in patients with pulmonary tuberculosis. These reactions can range from minor side effects such as nausea and headaches to severe complications like liver damage, hearing loss, and vision problems. In some cases, the adverse reactions can be life-threatening and require immediate medical attention. A study conducted by the WHO in 2018 found that adverse drug reactions were reported in 21% of patients receiving anti-tuberculosis drugs [1,2].

The causes of adverse reactions to anti-tuberculosis drugs are complex and multifactorial. Factors that increase the risk of adverse reactions include age, sex, liver disease, HIV infection, and malnutrition. The type of drug regimen used and the duration of treatment may also contribute to adverse reactions. The WHO recommends a standardized six-month drug regimen for the treatment of pulmonary tuberculosis, which includes a combination of four first-line drugs: isoniazid, rifampicin, ethambutol, and pyrazinamide.

Adverse reactions from anti-tuberculosis drugs can have significant implications for patient outcomes. For example, if a patient experiences a severe reaction and is unable to continue treatment, the risk of developing drug-resistant TB increases [3]. This not only complicates treatment but also increases the risk of transmission to others. Therefore, it is critical to identify and manage adverse reactions promptly to ensure successful treatment outcomes.

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

The causes of adverse reactions to anti-tuberculosis drugs are complex and multifactorial. Factors that increase the risk of adverse reactions include age, sex, liver disease, HIV infection, and malnutrition. The type of drug regimen used and the duration of treatment may also contribute to adverse reactions. The WHO recommends a standardized six-month drug regimen for the treatment of pulmonary tuberculosis, which includes a combination of four first-line drugs: isoniazid, rifampicin, ethambutol, and pyrazinamide [4].

Adverse reactions from anti-tuberculosis drugs can have significant implications for patient outcomes [5]. For example, if a patient experiences a severe reaction and is unable to continue treatment, the risk of developing drug-resistant TB increases. This not only complicates treatment but also increases the risk of transmission to others. Therefore, it is critical to identify and manage adverse reactions promptly to ensure successful treatment outcomes.

2. Methods

Adverse drug reactions (ADR) are a significant concern in the treatment of pulmonary tuberculosis (TB), especially for patients who are co-infected with HIV. The treatment of TB requires a combination of drugs that may cause a range of ADRs, including gastrointestinal disturbances, hepatotoxicity, and ototoxicity. Tuberculosis control programs have been struggling to implement effective strategies to monitor and manage ADRs in their patients. In this article, we aim to review the incidence, types, and management of ADRs in TB patients undergoing anti-TB therapy.

The incidence of ADRs to anti-TB drugs is high, and it varies widely among different patient populations. A study conducted in Nigeria found that 65% of patients experienced at least one ADR during treatment, with mild to moderate severity in most cases [6]. Another study from Iran reported that 83.7% of TB patients experienced at least one ADR, with hepatotoxicity being the most common (95.6%) [8]. A systematic review and meta-analysis showed that the overall incidence of ADRs to first-line anti-TB drugs was 32.6%, with hepatotoxicity being the most common ADR [10].

Hepatotoxicity is the most frequent and severe ADR associated with anti-TB drugs, especially to isoniazid (INH) and rifampicin (RIF). Early recognition and prompt management of hepatotoxicity are essential to prevent permanent liver damage or treatment interruption. Regular monitoring of liver function tests (LFTs) is recommended for all TB patients, especially those with pre-existing liver disease or receiving other hepatotoxic medications [9]. In case of LFT elevation, anti-TB drugs should be discontinued, and the patient re-evaluated for potential risk factors or alternative treatment options [7].

Gastrointestinal disturbances, such as nausea, vomiting, and diarrhea, are common side effects of anti-TB drugs, particularly with INH and pyrazinamide (PZA). These symptoms can affect the adherence to therapy and lead to negative health outcomes. Administering drugs with food or at bedtime and using symptomatic treatments such as antiemetics or antispasmodics can help alleviate these symptoms [9]. Ototoxicity, characterized by hearing loss and tinnitus, is a less frequent but potentially irreversible ADR associated with streptomycin (STM) use. Monitoring of audiometry is recommended in all TB patients receiving STM [9].

ADRs pose a significant challenge to the successful management of pulmonary TB. Health care providers must remain vigilant of ADRs and take proactive measures to prevent and manage them. Effective communication between TB patients and healthcare providers can improve the early detection and management of ADRs, leading to better treatment outcomes. Understanding the epidemiology, mechanisms, and risk factors of ADRs to anti-TB drugs can help optimize the selection and monitoring of TB therapy.

3. Results and Discussion

The most common adverse reactions to anti-tuberculosis drugs are gastrointestinal symptoms like nausea, vomiting, and diarrhea. These symptoms are usually mild and self-limiting, but in some cases, they can be severe enough to require discontinuation of the medication [11]. Other common adverse reactions include rash, pruritus, and fever. Severe adverse reactions, such as hepatic

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

toxicity and peripheral neuropathy, are less common but can be life-threatening.

The risk of adverse reactions to anti-tuberculosis drugs varies depending on the patient's age, sex, and comorbidities, as well as the type and duration of the medication. For example, older patients and those with pre-existing liver disease are at higher risk of developing hepatic toxicity. Patients with HIV co-infection are also at higher risk of developing adverse reactions, as they may be taking multiple medications that can interact with anti-tuberculosis drugs [12].

To reduce the risk of adverse reactions, healthcare providers should carefully assess patients for risk factors and monitor them closely during treatment. Patients should also be educated about the signs and symptoms of adverse reactions so that they can report them promptly. In cases where adverse reactions are severe or life-threatening, treatment may need to be modified or discontinued.

Adverse reactions to anti-tuberculosis drugs are common among patients with pulmonary tuberculosis. While most reactions are mild, severe reactions can occur and can lead to discontinuation of treatment [14]. Healthcare providers should carefully assess patients for risk factors and monitor them closely during treatment to reduce the risk of adverse reactions. Patients should also be educated about the signs and symptoms of adverse reactions so that they can report them promptly. Early recognition and management of adverse reactions can help ensure successful treatment outcomes for patients with pulmonary tuberculosis.

4. Conclusion

In conclusion, anti-tuberculosis drugs are essential in the treatment of pulmonary tuberculosis disease. These drugs, however, are associated with adverse reactions that may lead to poor treatment outcomes or even death if not effectively managed. Adverse drug reactions occur due to multiple factors such as genetic predisposition, age, sex, co-morbidities, and drug interactions. Some of the common anti-tuberculosis drugs associated with adverse reactions include Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide.

The management of adverse reactions in patients with pulmonary tuberculosis is critical to ensure the effectiveness of TB treatment. The monitoring of adverse drug reactions should be done regularly throughout the treatment period, and appropriate strategies for managing them should be put in place. Health care providers must assess their patients and determine the appropriate course of action for adverse reactions, which may range from dose reduction, drug switching, or discontinuation of therapy.

Several measures can be taken to reduce the incidence of adverse drug reactions to anti-tuberculosis drugs in patients with pulmonary tuberculosis. One of them is pre-treatment screening for co-morbidities such as HIV, diabetes, and liver or kidney disease, which may increase the risk of adverse reactions. Additionally, the use of bacteriologically confirmed TB diagnosis, adherence to the dosage regimen and comprehensive patient education is necessary.

Finally, in addition to pharmacovigilance, research should continue to strengthen the knowledge gap in relation to the mechanisms of actions of these drugs on different populations, novel drugs, and regimens. Studies should aim for personalized TB treatment approaches that take into account individual factors such as genetics, age, sex, and co-morbidities, among others. Ultimately, the successful management of adverse reactions associated with anti-tuberculosis drugs will improve TB treatment outcomes and support the global fight against TB eradication.

Acknowledgement

The completion of this article would not have been possible without the support and contributions of several individuals, to whom I am greatly indebted. First and foremost, I would like to acknowledge the patients with pulmonary tuberculosis who participated in clinical trials or provided data for this study. Their willingness to share their experiences and medical information was invaluable and central to the insights gained from this research.

I would like to extend my sincere appreciation to the healthcare professionals, including physicians, nurses, and researchers, who worked tirelessly to

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

treat and monitor patients with pulmonary tuberculosis. Their dedication to improving patient outcomes and advancing medical knowledge is inspiring, and their contributions to this research are deeply appreciated. Additionally, I would like to acknowledge the funding agencies and academic institutions that supported this study, which enabled us to carry out this important work. Finally, I would like to express my gratitude to the editorial and publishing teams who helped shape and refine this article.

References

1. World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.
2. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195.
3. Lee CH, Lee MC, Chang CH, et al. Adverse events of anti-tuberculosis drugs in hospitalized patients: a 10-year retrospective study. Int J Tuberc Lung Dis. 2013;17(3):357-364.
4. Alffenaar JW, Akkerman OW, Alves TM, et al. Precision dosing of anti-tuberculosis medication: the way forward. Lancet Infect Dis. 2020;20(3):e74-e83.
5. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192-202.
6. Abah, J. O., Omeje, E. U., Okwuzu, C. C., & Okoli, C. V. (2019). Profile of adverse drug reactions experienced by tuberculosis patients on therapy in a Nigerian tertiary hospital. Journal of Pharmacology and Pharmacotherapeutics, 10(3), 106–110. https://doi.org/10.4103/jpp.JPP_74_19
7. Alqahtani, J. M., Asiri, Y. A., Alshehri, S. A., & Alghamdi, R. S. (2018). Adverse drug reactions to antituberculosis drugs in Saudi Arabian patients. Clinical and Experimental Pharmacology and Physiology, 45(5), 497–502. https://doi.org/10.1111/1440-1681.12901
8. Shafiee, S., Bahrani, F., Kiaee, F., Esmaeili, S., Ziabakhsh Tabary, S.& Shahriarirad, R. (2019). Frequency of adverse drug reactions to tuberculosis drugs in patients with pulmonary tuberculosis in Golestan Province, Iran. Turkish Journal of Medical Sciences, 49(2), 565-570. https://doi.org/10.3906/sag-1808-153
9. World Health Organization. (2014). Treatment of Tuberculosis: Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK214422/
10. Wu, S., Zhang, Y., Sun, F., Chen, M., Zhou, L., Wang, N., & Zhan, S. (2016). Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. American journal of therapeutics, 23(2), e521-e530.
11. American Thoracic Society, Centers for Disease Control and Prevention, & Infectious Diseases Society of America. (2016). Treatment of drug-susceptible tuberculosis: Official ATS/CDC/IDSA clinical practice guidelines. Clin Infect Dis, 63(7), e147-e195. doi: 10.1093/cid/ciw376
12. Nahid, P., Dorman, S. E., Alipanah, N., et al. (2016). Executive summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis, 63(7), 853-867. doi: 10.1093/cid/ciw566
13. World Health Organization. (2019). WHO consolidated guidelines on tuberculosis: module 4: treatment—drug-resistant tuberculosis treatment. World Health Organization.
14. Sotgiu, G., Migliori, G. B., Centis, R., D'Ambrosio, L., Fernández-Vera, J. R., Spanevello, A., … & Blasi, F. (2016). Tuberculosis treatment and drug regimens. Cold Spring Harbor perspectives in medicine, 6(9), a022670.
15. Caminero, J. A. (2018). Management of drug-resistant tuberculosis. Drugs, 78(11), 1127-1153.
16. Singla, R., Gupta, R., & Sarin, R. (2011). Thirty years' experience of treating tuberculosis in a referral institute. The Indian Journal of Chest Diseases & Allied Sciences, 53(4), 179-184